A Multicenter and prospective observational study to evaluate the effectiveness and safety of Rosuzet Tablet in patients with acute ischemic stroke
Not Applicable
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0007080
- Lead Sponsor
- Chonnam National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
1) patients with acute ischemic stroke or transient ischemic attack with positive DWI lesions within 72 hours of onset and starting treatment with rosuzet within 3 days after admission; 2) one of following a to d items, a) previous station or ezetimibe treatment, b) previous atherothrombotic diseases, needed to statin or lipid lowering agents, c) dyslipidemia, d) admission LDL-C >70 mg/dl; 3) patients signed informed consent
Exclusion Criteria
1) contraindications of rosuzet, (1) sensitivity to rosuzet (rosuvastatin or ezetimibe), (2) active liver diseases, (3) muscle diseases, (4) cyclosporin treatment, (5) severe chronic kidney disease; 2) pregnant women or breastfeeding; 3) ineligible for the study
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rates of LDL-C <70mg at 3 months
- Secondary Outcome Measures
Name Time Method secondary outcomes: 1) rates of LDL-C <55mg at 3 months, 2) 3-months recurrent stroke, 3) in-hospital early neurological deterioration, 4) changes of LDL-C between baseline and 3-months